Gilead Sciences Inc vs Eli Lilly & Co.
GILD vs LLY — side-by-side comparison from reported financials. GILD leads 3, LLY leads 8 of 11 comparable metrics.
Gilead Sciences Inc
GILD · Healthcare
$151.20+2.79%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | GILD | LLY |
|---|---|---|
| Price | $151.20 | $1 177.20 |
| Market cap | $187B | $1.05T |
| Revenue (TTM) | $30.5B | $79.7B |
| Revenue growth | +2.6% | +31.7% |
| Net margin | -10.6% | 33.5% |
| Free cash flow | $12.9B | $18.2B |
| Net cash (debt) | ($24.9B) | ($35.2B) |
| 1-year price return | +29.5% | +37.6% |
| P/E | 22.0 | 41.6 |
| P/E vs own history (cheap-side %) | 78% | 88% |
| Dividend yield | 3.24% | 0.52% |
| Return on equity | -16% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 9 of 11 | 11 of 11 |
| Employees | 17,000 | 50,000 |
Full résumé-style profiles: GILD CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.